16,186 Shares in CeriBell (NASDAQ:CBLL) Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,186 shares of the company's stock, valued at approximately $419,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of CeriBell in the fourth quarter valued at $32,000. Summit Investment Advisors Inc. purchased a new position in CeriBell in the 4th quarter valued at about $33,000. Tower Research Capital LLC TRC purchased a new position in CeriBell in the 4th quarter valued at about $37,000. BNP Paribas Financial Markets acquired a new stake in shares of CeriBell during the fourth quarter valued at about $43,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the fourth quarter worth about $47,000.

CeriBell Stock Up 2.2%

NASDAQ:CBLL traded up $0.39 during mid-day trading on Friday, reaching $17.89. The stock had a trading volume of 235,568 shares, compared to its average volume of 280,585. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The stock's 50 day simple moving average is $16.59 and its two-hundred day simple moving average is $21.41.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. Sell-side analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Xingjuan Chao sold 5,700 shares of the stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now owns 746,451 shares in the company, valued at $11,211,694.02. This represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 74,700 shares of company stock valued at $1,221,434 over the last 90 days. 20.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CBLL. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell has an average rating of "Buy" and an average price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.